Anavex Life Sciences Corp (AVXL)

[sokol]

Bio: Brilliant research and analysis. I never would have made all of the connections, including the statement by Missling about being in good company with Lilly. You demonstrae too that Missling knows what he is doing although we sometimes have difficulity appreciating the progress Anavex has made under his leadership. Anavex’s progress, financially and clinically, has been gradual. However, I suspect we will see things pick up from here on now that Anavex has established sources of funding for completing existing trials and to add future trials. We will have four clinical trials in play in 2020, and I think more to come.


Additionally, below I cite findings that drug targets with genetic support are more likely to be approved. Here is the article:


Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval.
Emily A. King1*, J. Wade Davis1 & Jacob F. Degner1 1AbbVie Genomics Research Center, North Chicago, IL. January 7, 2019

"Analyzing historical pipeline data, Nelson et al. 2015 (Nat. Genet.) concluded pipeline drug targets with human genetic evidence of disease association are twice as likely to lead to approved drugs. Taking advantage of recent clinical development advances and rapid growth in GWAS datasets, we extend the original work using updated data, test whether genetic evidence predicts future successes and introduce statistical models adjusting for target and indication-level properties. Our work confirms drugs with genetically supported targets were more likely to be successful in Phases II and III. When causal genes are clear (Mendelian traits and GWAS associations linked to coding variants), we find the use of human genetic evidence increases approval from Phase I by greater than two-fold, and, for Mendelian associations, the positive association holds prospectively. Our findings suggest investments into genomics and genetics are likely to be beneficial to companies deploying this strategy"


https://www.biorxiv.org/content/biorxiv/early/2019/01/08/513945.full.pdf


Going forward, I believe we will see more and faster developments. Using a quote from someone: “There are decades when nothing happens, and weeks when decades happen,”

Thank you.